Caris & Co Upgrades Illumina (ILMN) to Above Average
ILMN Hot Sheet
Rating Summary:7 Buy, 11 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Caris & Co upgrades Illumina (Nasdaq: ILMN) from Average to Above Average. Price target increased to $42.
To see more analyst ratings on ILMN Click Here.
Illumina, Inc. engages in the development, manufacture, and marketing of integrated systems for the analysis of genetic variation and biological function.
To see more analyst ratings on ILMN Click Here.
Illumina, Inc. engages in the development, manufacture, and marketing of integrated systems for the analysis of genetic variation and biological function.
You May Also Be Interested In
- UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
- Deutsche Bank Upgrades Siemens (SI) to Buy; Subtle Shift
- UBS Maintains a 'Buy' on Teva Pharma (TEVA); CEO Highlights From Conference Call
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
